Western blot analysis of MUC18 was performed by loading 20 µg of HeLa (lane1) and HUVEC (lane2) cell lysate using Novex® NuPAGE® 12% Bis-Tris gel (NP0342BOX), XCell SureLock™ Electrophoresis System (EI0002), Novex® Sharp Pre-Stained Protein Standard (LC5800), and Proteins were transferred to a PVDF membrane and blocked with 5% skim milk for 1 hour at room temperature. MUC18 was detected at ~110 kDa using MUC 18 Mouse Monoclonal Antibody (357800) at 0.5-2 µg/mL in 2.5% skim milk at 4°C overnight on a rocking platform. Goat Anti-Mouse IgG - HRP Secondary Antibody (626520) at 1:4000 dilution was used and chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (WP20005).
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant human MUC18 (D1-D5) Fc protein|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||0.5-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MCAM plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. It could be an adhesion molecule active in neural crest cells during embryonic development. It acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2, and a transient increase in the intracellular calcium concentration.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Human||Not Cited||Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.||Sato A,Torii I,Okamura Y,Yamamoto T,Nishigami T,Kataoka TR,Song M,Hasegawa S,Nakano T,Kamei T,Tsujimura T||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (23:1458)||2010|